← back to search

Heather Lau

Yale University · US
Area of research
Physiology · Rheumatology
Research interest
Research interests include Lysosomal Storage Disorders Research, Glycogen Storage Diseases and Myoclonus, Trypanosoma species research and implications, and Cellular transport and secretion.
h-index
24
citations
1,861
works
112
NIH funding
primary concept
email

Recent publications

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)
Journal of Neurology 2024cited by 24position: middledoi
Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry
Journal of Clinical Medicine 2024cited by 12position: middledoi
Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry
Journal of Clinical Medicine 2024cited by 4position: middledoi
First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia B
Molecular Therapy 2022cited by 80position: middledoi
Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
Journal of Clinical Medicine 2022cited by 14position: middledoi
A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm
Orphanet Journal of Rare Diseases 2021cited by 46position: middledoi
Clinical outcomes after 4.5 years of eliglustat therapy for <scp>Gaucher</scp> disease type 1: Phase 3 <scp>ENGAGE</scp> trial final results
American Journal of Hematology 2021cited by 42position: middledoi
Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus
Molecular Genetics and Metabolism 2021cited by 37position: middledoi
Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
Molecular Genetics and Metabolism 2020cited by 31position: middledoi
Patients with Gaucher disease display systemic oxidative stress dependent on therapy status
Molecular Genetics and Metabolism Reports 2020cited by 25position: middledoi
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
American Journal of Hematology 2018cited by 76position: middledoi
Functional performance in late-onset GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases), longitudinal data over 3 consecutive years
Molecular Genetics and Metabolism 2018cited by 1position: middledoi
Aceneuramic Acid Extended Release Administration Maintains Upper Limb Muscle Strength in a 48-week Study of Subjects with GNE Myopathy: Results from a Phase 2, Randomized, Controlled Study
Journal of Neuromuscular Diseases 2016cited by 50position: middledoi
Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey
Blood Cells Molecules and Diseases 2016cited by 32position: firstdoi
Delivery of epilepsy care to adults with intellectual and developmental disabilities
Neurology 2015cited by 76position: middledoi
Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double‐blind, pilot study
American Journal of Medical Genetics Part A 2015cited by 39position: middledoi
Multi-domain impact of elosulfase alfa in Morquio A syndrome in the pivotal phase III trial
Molecular Genetics and Metabolism 2014cited by 73position: middledoi
Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II
Molecular Genetics and Metabolism 2014cited by 50position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ari Zimran · Hebrew University of Jerusalem5 papers (2016–2024)Özlem Göker-Alpan · National Human Genome Research Institute5 papers (2016–2024)Paul Harmatz · University of California, San Francisco4 papers (2014–2022)Patrick Deegan · Cambridge University Hospitals NHS Foundation Trust4 papers (2016–2024) · 4 papers (2014–2024) · 3 papers (2022–2024)Elena Lukina · Flinders University3 papers (2018–2024)Neal J. Weinreb · University of Miami3 papers (2020–2021)Jaco Botha · Novartis (Switzerland)3 papers (2022–2024) · 3 papers (2022–2024)Shoshana Revel‐Vilk · Hebrew University of Jerusalem3 papers (2022–2024)Manisha Balwani · University of Miami3 papers (2020–2021) · 2 papers (2016–2024)Priya S. Kishnani · University of Kentucky2 papers (2020–2021)Pramod K. Mistry · Yale Cancer Center2 papers (2020–2021) · 2 papers (2018–2021) · 2 papers (2024–2024) · 2 papers (2020–2021)Meredith C. Foster · Sanofi (United States)2 papers (2018–2021)Julian Raiman · Hospital for Sick Children2 papers (2014–2014)